Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
9,891.00
-65.00 (-0.65%)
At close: Jan 28, 2026
25.39%
Market Cap118.12B
Revenue (ttm)55.02B +4.3%
Net Income4.50B
EPS3.86
Shares Outn/a
PE Ratio26.28
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,459,644
Average Volume1,619,079
Open9,777.00
Previous Close9,956.00
Day's Range9,450.00 - 10,160.00
52-Week Range4,865.00 - 11,100.00
Beta0.66
RSI50.13
Earnings DateJan 28, 2026

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 37,000
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript

Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript

12 hours ago - Seeking Alpha

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, ...

14 hours ago - Benzinga

Teva Pharmaceutical Industries Limited 2025 Q4 - Results - Earnings Call Presentation

2026-01-28. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2025 Q4 earnings call.

15 hours ago - Seeking Alpha

Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals

Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals

17 hours ago - GuruFocus

TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals

TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals

17 hours ago - GuruFocus

TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies

TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies

17 hours ago - GuruFocus

Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Teva Pharmaceutical Industries (TEVA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metri...

17 hours ago - Nasdaq

TEVA Aims to Double Biosimilar Revenue by 2027

TEVA Aims to Double Biosimilar Revenue by 2027

17 hours ago - GuruFocus

TEVA: Progress in Transformation Initiatives and Future Financial Expectations

TEVA: Progress in Transformation Initiatives and Future Financial Expectations

18 hours ago - GuruFocus

Teva Pharma Slides On Light 2026 Outlook Despite Fourth-Quarter Beat

Teva stock slipped early Wednesday on light 2026 guidance. The drugmaker, known for generics, easily beat fourth-quarter forecasts.

18 hours ago - Investor's Business Daily

Teva Pharmaceutical (TEVA) Surpasses Q4 Expectations with Strong Earnings

Teva Pharmaceutical (TEVA) Surpasses Q4 Expectations with Strong Earnings

18 hours ago - GuruFocus

Teva Pharmaceutical (TEVA) Surpasses Q3 Earnings Expectations

Teva Pharmaceutical (TEVA) Surpasses Q3 Earnings Expectations

18 hours ago - GuruFocus

Teva (TEVA) Projects Lower 2026 Financials Despite Q4 2025 Beat

Teva (TEVA) Projects Lower 2026 Financials Despite Q4 2025 Beat

18 hours ago - GuruFocus

Teva (TEVA) Reports Strong Q4 Revenue, Highlights Growth Strategy

Teva (TEVA) Reports Strong Q4 Revenue, Highlights Growth Strategy

19 hours ago - GuruFocus

Teva (TEVA) Reports Robust Growth and Strategic Advancements in 2025

Teva (TEVA) Reports Robust Growth and Strategic Advancements in 2025

19 hours ago - GuruFocus

TEVA Projects Revenue Growth with Promising Pipeline Developments

TEVA Projects Revenue Growth with Promising Pipeline Developments

19 hours ago - GuruFocus

Teva Pharmaceutical profit, revenue rise in fourth quarter

Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in fourth-quarter profit, boosted by sales of its branded drugs as well as a milestone payment to begin a late stage st...

19 hours ago - Reuters

Teva Pharmaceutical Turns To Profit In Q4, Announces FY26 Outlook

(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributable to the compa...

19 hours ago - Nasdaq

Teva Pharmaceutical Industries Q4 25 Earnings Conference Call At 8:00 AM ET

(RTTNews) - Teva Pharmaceutical Industries (TEVA) will host a conference call at 8:00 AM ET on January 28, 2026, to discuss Q4 25 earnings results.

19 hours ago - Nasdaq

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Ja...

19 hours ago - GlobeNewsWire

Earnings Scheduled For January 28, 2026

Companies Reporting Before The Bell • VF (NYSE: VFC) is estimated to report quarterly earnings at $0.43 per share on revenue of $2.76 billion. • Elevance Health (NYSE: ELV) is estimated to report qu...

20 hours ago - Benzinga

Teva Pharmaceutical (TEVA) Q4 Earnings Preview: What to Expect

Teva Pharmaceutical (TEVA) Q4 Earnings Preview: What to Expect

1 day ago - GuruFocus